drug · small molecule
SYMDEKO (COPACKAGED)
updated 6mo ago/ EYE-və-KAF-tər /
by $VERX Vertex, Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval286 co-mentions · 91 sources
- drugORKAMBI253 co-mentions · 91 sources
- drugKALYDECO233 co-mentions · 91 sources
- drugivacaftor233 co-mentions · 91 sources
- tagSmall Molecule143 co-mentions · 91 sources
- drugTRIKAFTA (COPACKAGED)38 co-mentions · 19 sources
- drug(ivacaftor + lumacaftor)20 co-mentions · 20 sources
- drug(elexacaftor + ivacaftor + tezacaftor) + ivacaftor19 co-mentions · 19 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.
targets
Cystic fibrosis transmembrane conductance regulator
all catalysts(0)
nothing on the calendar yet
Trials studying SYMDEKO (COPACKAGED)
- phase1Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
- phase2A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
- phase2Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
- phase2The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor
- phase1Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated Tablets
- phase2A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
- phase2Gut Imaging for Function & Transit in Cystic Fibrosis Study 2
News(1)
- Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict loomsAnalysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.biospace · 1d ago
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that